Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Rosiver Ivermectin Rosacea List with criteria/condition Complete
Rozlytrek Entrectinib ROS1-positive NSCLC Reimburse with clinical criteria and/or conditions Complete
Rozlytrek entrectinib Extracranial solid tumours with NTRK gene fusion Reimburse with clinical criteria and/or conditions Complete
Rukobia fostemsavir Human immunodeficiency virus type 1 (HIV-1) Reimburse with clinical criteria and/or conditions Complete
Ruzurgi amifampridine Lambert-Eaton myasthenic syndrome Reimburse with clinical criteria and/or conditions Complete
Ryaltris olopatadine hydrochloride and mometasone Seasonal allergic rhinitis Active
Rybelsus semaglutide diabetes mellitus, type 2 Reimburse with clinical criteria and/or conditions Complete
Rybrevant amivantamab Non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Rybrevant amivantamab Locally advanced or metastatic non-small cell lung cancer (NSCLC) Active
Rybrevant amivantamab Locally advanced or metastatic non-small cell lung cancer (NSCLC) Pending